Published in Women's Health Weekly, August 19th, 1996
AltaRex intends to enroll more than 200 patients with advanced ovarian cancer in this study. "We are very pleased to achieve this important milestone, and to be able to bring the benefits of the technology we have tested in Europe for a number of years to North America," said Dr. A. Noujaim, the AltaRex's president and CEO.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.